Serous ovarian carcinoma patients with high alpha‐folate receptor had reducing survival and cytotoxic chemo‐response

Abstract

Published by Elsevier B.V. All rights reserved. IntroductionOvarian carcinoma has become more and more important in recent years because it is the leading cause of death among all gynecologic malignancies (Boyle et al., 2000).

In-depth research of multidrug resistance related cell surface glycoproteome in gastric cancer

“…Totally 11 glycoproteins were found simultaneously elevated or decreased in both SGC7901/VCR and SGC7901/ADR cell lines. 9 of these 11 proteins (Mesothelin; EGFR; Integrin alpha-3; CD59; Folate receptor alpha; Peptidyl-prolyl cis-trans isomerase FKBP9; Laminin subunit alpha-5; Dihydropyridine receptor alpha 2; Multidrug resistance protein 1) have been reported to associate with multidrug resistance in various kinds of cancers and the rest have not been revealed (Prostaglandin F2 receptor negative regulator; Golgi apparatus protein 1) [34,[42][43][44][45][46][47][48][49]. On the one hand, the identification of foregone MDR-related glycoproteins confirmed the accuracy [50] and reliability of our study and may provide new prospect for these molecules in gastric cancer.…”

Imaging the Folate Receptor on Cancer Cells with 99mTc-Etarfolatide: Properties, Clinical Use, and Future Potential of Folate Receptor Imaging

“…Several methods have been used for FR detection, such as immunohistochemistry, polymerase chain reaction, quantitation polymerase chain reaction, or in situ hybridization (5,6). Although these methods can have high specificity and sensitivity, their clinical use requires a biopsy, typically taken only once of a single lesion.…”

“…Because FR expression is prognostic for ovarian and lung cancer, 99m Tc-etarfolatide imaging may be used as a prognostic tool (6,28). Intraoperative FR imaging with optical probes can improve staging and facilitates cytoreductive surgery (29).…”

“…Few nonmalignant tissues, such as epithelial cells in the kidney and placenta, show FR expression, as most cells use the reduced folate carrier for folate transport (4). For some tumors, such as ovarian cancer, FR expression is associated with tumor stage and grade and is a negative prognostic factor (5,6). FRs are involved in tumor progression in various ways.…”

“…First, the fact that FRs transport folate into cells appears to support proliferation of malignant cells (7). Second, FR expression was found to be associated with chemotherapy resistance in ovarian cancer, potentially by mediating apoptosis resistance (6). Third, FR expression seems to support cell motility, as its expression in ovarian cancer is associated with downregulated E-cadherin expression (7).…”